SCHEMBL7808969

SCHEMBL7808969

CC(CF)Nc1nc2cc(Cl)c(Cl)cc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
AR P10275 3/20 0.45
CACNA1G O43497 2/20 0.38
CACNA1H O95180 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
PRKAG1 P54619 2/20 0.38
PRKAA2 P54646 2/20 0.38
PRKAB1 Q9Y478 2/20 0.38
PRKAA1 Q13131 1/20 0.38
S1PR2 O95136 1/20 0.37
RHEB Q15382 3/20 0.37
GRIN2D O15399 2/20 0.36
GRIN3B O60391 2/20 0.36
GRIA1 P42261 2/20 0.36
GRIA2 P42262 2/20 0.36
GRIA3 P42263 2/20 0.36
GRIA4 P48058 2/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2A Q12879 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29720357 0.83 GAA (0.49) GAAHTTARCACNA1GCACNA1H
SCHEMBL439758 0.83 GAA (0.49) GAAHTTARCACNA1GCACNA1H
SCHEMBL7734462 0.75 AR (0.40) GAAHTTAREGLN1S1PR2
SCHEMBL31265260 0.73 GAA (0.57) GAAHTTARCACNA1GCACNA1H
SCHEMBL27241025 0.73 GAA (0.57) GAAHTTARCACNA1GCACNA1H
SCHEMBL7122061 0.71 AR (0.43) ARCACNA1HEGLN1
SCHEMBL7113015 0.71 EGLN1 (0.39) GAAHTTAREGLN1LMNA
SCHEMBL7215070 0.70 GAA (0.49) GAAHTTARCACNA1GCACNA1H
SCHEMBL29770400 0.68 EGLN1 (0.44) GAAHTTARCACNA1GEGLN1
SCHEMBL29770320 0.68 PRSS12 (0.48) GAAHTTARCACNA1GEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010003744-A1 Therapeutic compounds CHAMBERLAIN STANLEY DAWES (US) 2001-06-14 US claimed
US-6307043-B1 FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS GLAXO WELLCOME INC. 2001-10-23 US disclosed
US-20010003744-A1 Therapeutic compounds CHAMBERLAIN STANLEY DAWES (US) 2001-06-14 US disclosed
US-6077832-A FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION GLAXO WELLCOME INC. (US) 2000-06-20 US disclosed
EP-0769017-B1 THERAPEUTIC COMPOUNDS WELLCOME FOUND (GB) 2000-05-24 EP disclosed
US-5998605-A Antiviral benzimidazole nucleoside analogues and method for their preparation GLAXO WELLCOME INC. (US) 1999-12-07 US disclosed
WO-1996001833-A1 THERAPEUTIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1996-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010003744-A1 Therapeutic compounds ZC3HAV1, HAVCR2, EIF2AK2 GAA 98/4885HTT 2409/4885AR 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.